316 related articles for article (PubMed ID: 25365404)
1. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
[TBL] [Abstract][Full Text] [Related]
2. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis.
Wang R; Lin Q; Lu Z; Wen H; Hu F; You J; He Y; Fang Y; Bian Z; Hou Q; Ju Z; Wang Y; Lian M; Xiao X; Sheng L; Guo C; Hua J; Tang R; You Z; Chen X; Gershwin ME; Huang Z; Wang Q; Miao Q; Ma X
J Autoimmun; 2024 Feb; 143():103163. PubMed ID: 38301505
[TBL] [Abstract][Full Text] [Related]
4. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
5. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
7. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
[TBL] [Abstract][Full Text] [Related]
8. Development of autoimmune hepatitis in primary biliary cirrhosis.
Gossard AA; Lindor KD
Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
[TBL] [Abstract][Full Text] [Related]
9. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.
Heurgué A; Vitry F; Diebold MD; Yaziji N; Bernard-Chabert B; Pennaforte JL; Picot R; Louvet H; Frémond L; Geoffroy P; Schmit JL; Cadiot G; Thiéfin G
Gastroenterol Clin Biol; 2007 Jan; 31(1):17-25. PubMed ID: 17273128
[TBL] [Abstract][Full Text] [Related]
10. [The clinical observation of different therapeutic strategies in combined primary biliary cirrhosis and Sjögren syndrome].
Gao LX; Zhang FC; Wang L; Zhang X; Liu B
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):851-4. PubMed ID: 23291020
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.
Fan X; Zhu Y; Men R; Wen M; Shen Y; Lu C; Yang L
Can J Gastroenterol Hepatol; 2018; 2018():1965492. PubMed ID: 30155449
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
17. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
[TBL] [Abstract][Full Text] [Related]
19. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
20. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study.
Zhu J; Shi Y; Zhou X; Li Z; Huang X; Han Z; Wang J; Wang R; Ding J; Wu K; Han Y; Fan D
Front Med; 2013 Jun; 7(2):255-63. PubMed ID: 23179137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
